Pierre Laurent-Puig is an expert in Oncology at Hôpital Européen Georges-Pompidou (France). As of October 2026, ScienceLeadR ranks Pierre Laurent-Puig in the top 1% of experts worldwide for Intestinal Neoplasms, Gastrointestinal Neoplasms and Colonic Diseases. Pierre Laurent-Puig has authored 768 publications, the most recent in 2026, and is an investigator in 23 clinical trials, 1 of them ongoing. SLR score: 3,182 (community average: 125). How the SLR is computed.

LeadR Profile

Pierre Laurent-Puig Hôpital Européen Georges-Pompidou France
3 182 ScienceLeadR Reputation 3182
Network Map

Oncology

Subspecialties: Gynecology - Gastroenterology - Genetics

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 1993 - 2026

Source: PubMed

Université Paris Cité

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 768

Citations

Citations: 60 985 1st author: 42 Last author: 160 Unique author: 11


Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Baseline circulating and tumor γδ T cells and early circulating CD8⁺PD1⁺ expansion predict response to Atezolizumab-bevacizumab in HCC.
PMID 42606323 — cells, neoplasms, sorafenib, bevacizumab, immunotherapy, therapeutics
Clin Cancer Res20260
Prognostic and Predictive Values of Transcriptomic Signatures in Metastatic Pancreatic Cancer: A Biomarker Analysis of Three French Multicenter Prospective Randomized Controlled Phase 2 Trials (Prodige35, Prodige37 and AFUGEM).
PMID 42521075 — pancreatic neoplasms, neoplasms, predictive value of tests, biomarkers, research
Cancer Lett20260
Molecular Profiling of Urothelial Bladder Cancer: Bridging Tumor Biology and Clinical Decision-making.
PMID 42420157 — urinary bladder, urinary bladder neoplasms, genes, muscles, clinical decision-making, neoplasms, chromatin, decision making, biomarkers, therapeutics, mutation, non-muscle invasive bladder neoplasms
Eur Urol Oncol20260
Circulating tumour DNA in patients with colorectal cancer undergoing curative-intent LIver MEtastases Surgery in France: a prospective, multicentre GERCOR G-118 CLIMES PRODIGE 77 cohort study protocol.
PMID 42379715 — neoplasms, cohort studies, drug therapy, liver, neoplasm metastasis, therapeutics, colorectal neoplasms, dna, prognosis, chemotherapy
BMJ Open20260
Association between dietary intakes and gut microbiota composition in individuals with Lynch syndrome: a cross-sectional analysis of the AAS-Lynch study.
PMID 42214493 — cross-sectional studies, plant proteins, meat, neoplasms, red meat, diet, analysis of variance, gastrointestinal microbiome, microbiota, dietary patterns
Am J Clin Nutr20260

Clinical Studies 23

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 5 Study Director: 2

By phase:

N/A 10
Phase 2 6
Phase 3 6
Phase 1/Phase 2 1

By status:

Completed 10
Unknown 6
Active not recruiting 4
Not yet recruiting 1
Recruiting 1
Terminated 1

By type:

Interventional 14
Observational 9

By Monocentric/Multicentric:

monocentric 9
multicentric2to4 2
multicentric5to9 3
multicentricup10 9

Main Topics

Ongoing Clinical Trials

Ongoing trial started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Impact of Exercise and Hyperlipidic Meal on Free Circulating DNA in Patients With Metastatic Colonic Cancer and Healthy Subjects
NCT05147545 — exercise, pilot projects, pilots, stomach, eating, neoplasms, colon, healthy volunteers, meals, physical exertion, dna, sports, colonic neoplasms
N/ANot yet recruiting2023

LeadR Networks

Main global connection map